Key points are not available for this paper at this time.
Clinical distinctions between cholangiocarcinoma (particularly intrahepatic cholangiocarcinoma ICC) and cancer of unknown primary (CUP) can be challenging. Recent discoveries have identified recurrent and potentially targetable genomic abnormalities in ICC, highlighting the importance of improving diagnosis. This study demonstrates that the incidence of ICC is increasing in the U.S., whereas the incidence of extrahepatic cholangiocarcinoma is stable. Concomitantly, the incidence of CUP has declined dramatically, suggesting that improved distinction between ICC and CUP may be a major driver of the increasing recognized incidence of ICC. The increasing incidence of ICC warrants further study of prevention and treatment approaches.
Building similarity graph...
Analyzing shared references across papers
Loading...
Supriya K. Saha
Andrew X. Zhu
Charles S. Fuchs
The Oncologist
Harvard University
Massachusetts General Hospital
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Saha et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69d7335cb54ccf0cfef30787 — DOI: https://doi.org/10.1634/theoncologist.2015-0446
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: